HOME

ABOUT

OUR TECHNOLOGIES

PUBLICATIONS AND NEWS

News

March 1, 2018-

The National Institutes of Health/National Cancer Institute awards Immune Modulatory Therapies LLC a Small Business Innovation Research grant Reversing/Blocking T-Cell Suppression by Extra-cellular Vesicles as Cancer Therapy with IMT Associate Director of Research and Development and Senior Scientist Dr. Maulasri Bhatta as Principal Investigator.

September 14, 2018-

The Center for Advanced Technologies awards Immune Modulatory Therapies LLC a grant to study the Big Data aspects of Reversing/Blocking T-Cell Suppression by Extra-cellular Vesicles as Cancer Therapy with Dr. Sathy Balu-Iyer as Principal Investigator.

March 15, 2021-

The National Institutes of Health/National Cancer Institute awards Immune Modulatory Therapies LLC a Small Business Innovation Research grant Novel Drug for Cancer Immunotherapy that Targets Phosphatidylserine with Dr. Richard Bankert as Principal Investigator.

July 1, 2021-

The Center for Advanced Technologies awards Immune Modulatory Therapies LLC a grant to study the Big Data aspects of using liposome encapsulated IL-12 as an expanded scope for Reversing/Blocking T-Cell Suppression by Extra-cellular Vesicles as Cancer Therapy with Dr. Thomas Melendy as Principal Investigator.

Publications of Research and Sponsored Research

G. N. Shenoy, M. Bhatta, J. L. Loyall, R. J. Kelleher, Jr., J. M. Bernstein, R. B. Bankert Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments. Immunol Invest 49, 726-743 (2020).

G. N. Shenoy, C. J. Greene, M. Bhatta, M. L. Baroja, J. L. Loyall, S. V. Balu-Iyer, R. J. Kelleher, Jr., B. M. Carreno, G. P. Linette, L. D. Shultz, R. B. Bankert Preclinical evaluation of cancer immune therapy using patient-derived tumor antigen-specific T cells in a novel xenograft platform Clin Transl Immunology 10, e1246 (2021).